473A Stock Overview
A clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$1.44 |
| 52 Week Low | US$0.24 |
| Beta | 2.51 |
| 1 Month Change | -54.17% |
| 3 Month Change | -56.70% |
| 1 Year Change | -83.14% |
| 3 Year Change | -87.45% |
| 5 Year Change | -90.63% |
| Change since IPO | -98.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 473A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -40.1% | 0.4% | -1.3% |
| 1Y | -83.1% | -14.3% | 13.1% |
Return vs Industry: 473A underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 473A underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| 473A volatility | |
|---|---|
| 473A Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 473A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 473A's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 449 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc Fundamentals Summary
| 473A fundamental statistics | |
|---|---|
| Market cap | €68.78m |
| Earnings (TTM) | -€41.15m |
| Revenue (TTM) | €161.79m |
0.4x
P/S Ratio-1.7x
P/E RatioIs 473A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 473A income statement (TTM) | |
|---|---|
| Revenue | US$175.04m |
| Cost of Revenue | US$143.17m |
| Gross Profit | US$31.87m |
| Other Expenses | US$76.39m |
| Earnings | -US$44.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 18.21% |
| Net Profit Margin | -25.43% |
| Debt/Equity Ratio | 62.3% |
How did 473A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:22 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adaptimmune Therapeutics plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |
| Olga Smolentseva | Bryan Garnier & Co |